Evidence map›Paper›PMID 36140162›Full record

ArticleBiomedicines2022

Clinical Impact of Monoclonal Antibodies in the Treatment of High-Risk Patients with SARS-CoV-2 Breakthrough Infections: The ORCHESTRA Prospective Cohort Study.

Alessia Savoldi, Matteo Morra, Alessandro Castelli, Massimo Mirandola, Matilda Berkell, Mathias Smet, Angelina Konnova, Elisa Rossi, Salvatore Cataudella, Pasquale De Nardo and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 5 countries.

Alessia SavoldiDivision of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, P.le L.A. Scuro 10, 37134 Verona, Italy.ORCID 0000-0003-1873-5323
Matteo MorraDivision of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, P.le L.A. Scuro 10, 37134 Verona, Italy.ORCID 0000-0002-1684-0261
Alessandro CastelliDivision of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, P.le L.A. Scuro 10, 37134 Verona, Italy.
Massimo MirandolaDivision of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, P.le L.A. Scuro 10, 37134 Verona, Italy.ORCID 0000-0002-2342-5867
Matilda BerkellLab of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, 2610 Antwerp, Belgium.ORCID 0000-0002-7096-7896
Mathias SmetLab of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, 2610 Antwerp, Belgium.
Angelina KonnovaMolecular Pathology Group, Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium.ORCID 0000-0001-9353-8026
Elisa RossiCINECA-Interuniversity Consortium, Via Magnanelli 6/3, Casalecchio di Reno, 40033 Bologna, Italy.
Salvatore CataudellaCINECA-Interuniversity Consortium, Via Magnanelli 6/3, Casalecchio di Reno, 40033 Bologna, Italy.
Pasquale De NardoDivision of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, P.le L.A. Scuro 10, 37134 Verona, Italy.ORCID 0000-0002-4433-0138
Elisa GentilottiDivision of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, P.le L.A. Scuro 10, 37134 Verona, Italy.
Akshita GuptaMolecular Pathology Group, Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium.
Daniele FasanDivision of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, P.le L.A. Scuro 10, 37134 Verona, Italy.
Enrico GibbinDivision of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, P.le L.A. Scuro 10, 37134 Verona, Italy.
Filippo Cioli PuvianiDivision of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, P.le L.A. Scuro 10, 37134 Verona, Italy.
Jan HasenauerHelmholtz Center Munich-Germany Research Center for Environmental Heath, Institute for Computational Biology, 85764 Neuherberg, Germany.
Roy GusinowHelmholtz Center Munich-Germany Research Center for Environmental Heath, Institute for Computational Biology, 85764 Neuherberg, Germany.
Adriana TamiDepartment of Medical Microbiology & Infection Prevention, University Medical Center Groningen, 9713 AV Groningen, The Netherlands.ORCID 0000-0002-1918-9144
Samir Kumar-SinghMolecular Pathology Group, Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium.ORCID 0000-0001-9466-6732
Surbhi Malhotra-KumarLab of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, 2610 Antwerp, Belgium.
mAb Orchestra Working Group
Evelina TacconelliDivision of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, P.le L.A. Scuro 10, 37134 Verona, Italy.
University of Verona · ITUniversity of Antwerp · BECineca · ITUniversity of Bonn · DEUniversity Medical Center Groningen · NL

Funding

European Union's Horizon 2020 research and innovation programme 101016167
6 · The paper itself

Abstract

The clinical impact of anti-spike monoclonal antibodies (mAb) in Coronavirus Disease 2019 (COVID-19) breakthrough infections is unclear. We present the results of an observational prospective cohort study assessing and comparing COVID-19 progression in high-risk outpatients receiving mAb according to primary or breakthrough infection. Clinical, serological and virological predictors associated with 28-day COVID-19-related hospitalization were identified using multivariate logistic regression and summarized with odds ratio (aOR) and 95% confidence interval (CI). A total of 847 COVID-19 outpatients were included: 414 with primary and 433 with breakthrough infection. Hospitalization was observed in 42/414 (10.1%) patients with primary and 8/433 (1.8%) patients with breakthrough infection (

Indexed as

anti-spike monoclonal antibodiesCOVID-19 breakthrough infectionCOVID-19 early treatment

Identifiers

PMID36140162
PMCPMC9495697
OpenAlexW4293008703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.